Diagnostic potential for urinary proteomics

Pharmacogenomics

Volumn 8, Issue 3, 2007, Pages 237-255

  Hortin, Glen L ^a   Sviridov, Denis ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Kidney disease; Microalbumin; Microglobulins; Nephrotoxins; Urinary peptidomic; Urinary proteomics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 1 MICROGLOBULIN; AMINO TERMINAL TELOPEPTIDE; BETA 2 MICROGLOBULIN; C PEPTIDE; CYSTATIN C; ESTERASE; FATTY ACID BINDING PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE P1; HEMOGLOBIN; HYDROXYPROLINE; IMMUNOGLOBULIN G; LUTEINIZING HORMONE; METALLOTHIONEIN; MYOGLOBIN; N ACETYL BETA GLUCOSAMINIDASE; NUCLEAR MATRIX PROTEIN 22; OSTEOCALCIN; PLASMA PROTEIN; PROTEOME; RETINOL BINDING PROTEIN; TRANSFERRIN; TRYPSINOGEN; TUMOR ANTIGEN; ULINASTATIN;

BLADDER CANCER; BONE TURNOVER; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; HEAVY METAL POISONING; HEMATURIA; HEMOGLOBINURIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TUBULE DAMAGE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL TECHNOLOGY; MOLECULAR WEIGHT; MUSCLE INJURY; NEPHROTOXICITY; NON INVASIVE PROCEDURE; PANCREATITIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; PROTEOMICS; REVIEW; RHABDOMYOLYSIS; SENSITIVITY ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMIC DISEASE; TWO DIMENSIONAL GEL ELECTROPHORESIS; ULTRAFILTRATION; URINALYSIS; URINARY EXCRETION; URINARY TRACT INFECTION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; PROTEINURIA; PROTEOMICS; UROLOGIC DISEASES;

EID: 33947574141     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.3.237     Document Type: Review

References (169)

1. Anderson NG, Anderson NL, Tollaksen SL: Proteins of human urine. I. Concentration and analysis by two-dimensional electrophorests. Clin. Chem. 25, 1199-1210 (1979).
2. Pieper R, Gatlin CL, McGrath AM et al.: Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimension electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics 4, 1159-1174 (2004).
3. Oh J, Pyo JH, Jo EH et al.: Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics 4, 3485-3497 (2004).
4. Castagna A, Cecconi D, Sennels et al.: Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res. 4, 1917-1930 (2005).
5. Sun W, Li F, Wu S et al.: Human urine proteome analysis by three separation approaches. Proteomics 5, 4994-5001 (2005).
6. Khan A, Packer NH: Simple urinary sample preparation for proteornics analysis. J. Proteome Res. 5, 2824-2838 (2006).
7. Zerefos PG, Vougas K, Dimitraki P et al.: Characterization of the human urine proteorne by preparative electophoresis In combination with 2-DE. Proteomics 6, 4346-4355 (2006).
8. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1500 proteins including a large proportion of membrane proteins. Genome Biol. 7(R80), 1-16 (2006).
9. Heine G, Raida M, Forssmann WG: Mapping of pepticles and protein fragments in human urine using liquid chromatography mass spectrometry J. Chromatog. A 776, 117-124 (1997).
10. Cutillas PR, Norden AG, Cramer R et al.: Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: application to patients with renal Fanconi syndrome. Clin. Sci. (Lond) 104, 483-490 (2003).
11. Wittke S, Mischak H, Walden M, Kolch W, Radler T, Wiedemann K: Discovery of blomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis 26, 1476-1487 (2005).
12. Jurgem M, Appel A, Heine G et al.: Towards characterization of the human urinary peptidome. Comb. Chem. High Throughput Screening 8, 757-765 (2005).
13. Viahou A, Schellhammer PF. Mendrinos S et al.: Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158, 1491-1502 (2001).
14. Hampel DJ, Sansome C, Sha M et al.: Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration. J. Am. Soc. Nephrol. 12, 1026-1035 (2001).
15. Spahr CS, Davis MT, McGinley MD et al.: Towards defining the urinary proteome using liquid chromatography tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 1, 93-107 (2001).
16. Lafitte D, Dussol B, Andersen S et al.: Optimized preparation of urine samples for two-dimensional electrophoresis and initial application to patient samples. Clin. Biochem. 35, 581-589 (2002).
17. Rehman I, Azzouzi AR, Catto JW et al.: Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study. Urology64, 1238-1243 (2004).
18. Schaub S, Wilkins J, Weiler T et al.: Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-filght mass spectrometry. Kidney Int. 65, 323-332 (2004).
19. Van QN, Klose JR, Lucas DA et al.: The use of urine proteomic and metabonornic patterns for the diagnosis of Interstitial cystitis and bacterial cystitis. Dis. Markers 19, 169-183 (2003-2004).
20. Zhang YF, Wu DL, Guan M et al.: Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 37, 772-779 (2004).
21. Cutillas PR, Chalkley RJ, Hansen KC et al.: The urinary proteome in Fanconi syndrome Implies specificity in the reabsorption of proteins by renal proximal tubule cells. Am. J Physiol. Renal Physiol. 287, F353-F364 (2004).
22. Hortin GL, Mellinger B, Drake SK: Size-selective extraction of peptides from urine for mass spectrometric analysis. Clin. Chem. 50, 1092-1095 (2004).
23. Pisitkun T, Shen RF, Knepper MA: Identification and proteomic profiling of exosomes in human urine. Proc. Natl Acad. Sci. 101, 13368-13373 (2004).
24. Braun MC, Li L, Ke B et al.: Proteomic profiling of urinary protein excretion in the factor H-deficient mouse. Am. J. Nephrol. 26, 127-135 (2006).
25. Ye B, Skates S, Mok SC et al.: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer In urine. Clin. Cancer Res. 12, 432-441 (2006).
26. Lin CY, Tsui-,KH, Yu CC, Yeh CW, Chang PL, Yung BY Searching cell-secreted proteomes for potential urinary bladder tumor markers. Proteomics 6, 4381-4389 (2006).
27. Park MR, Wang EH, Jin DC et al.: Establishment of a 2D human urinary proteomic map in IgA nephropathy, Proteomics 6, 1066-1076 (2006).
28. Krishna J, Shah ZA, Merchant M, Klein JB, Gozai D: Urinary protein expression patterns in children with sleep-disordered breathing: preliminary findings. Sleep Med 7, 221-227 (2006).
29. Khurana M, Traum AZ, Aivado M et al.: Urine proteomic profiling of pediatric nephritic syndrome. Pediatr. Nephrol. 21, 1257-1265 (2006).
30. Ngaa HH, Sit WH, Jiang PP. Xu RJ, Wan JM, Thongboonkerd V: Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J. Proteome Res. 5. 3038-3047 (2006).
31. Soldi M, Sarto C,.Valscchi C et al.; Proteome proftle of human urine with two-dimensional liquid phase fractionation. Proteomics 5, 2641-2647 (2005).
32. Thongboonkerd V, Chutipongtanate S, Kardaya R: Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J. Proteome Res. 5, 183-191 (2006).
33. Traum AZ, Wells MP, Aivado M et al.: SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 6, 1676-1680 (2006).
34. Fiedler GM, Baumann S. Leichde A et al.: Standardized peptidome profiling of human urine using magnetic-bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. (2007) (In Press).
35. Ferguson RE, Selby PJ, Banks RE: Proteomic studies in urological malignancies. Contrib. Nephrol. 141, 257-279 (2004).
36. Ransom RF: Podocyte proteomics. Contrib. Nephrol. 141, 189-211 (2004).
37. Witzmann FA, Li J: Proteomics and nephrotoxicity. Contrib. Nephrol. 141, 104-123 (2004).
38. Chevalier RL: Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat. Clin. Prac. Nephrol. 2, 157-168 (2005).
39. Tbongboonkerd V, Malasit P: Renal and urinary proteomics: current applications and challenges. Proteomics 5, 1033-1042 (2005).
40. Merchant ML, Klein JB: Proteomics and diabetic nephropathy Curr. Diab. Rep. 5, 464-469 (2005).
41. Pisitkun T, Johnstone R, Knepper MA: Discovery of urinary blomarkers. Mol. Cell. Proteomics 5, 1760-1771 (2006).
42. Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RK Pennington SR. Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers 11, 406-416 (2006).
43. O'Riordan E, Gross SS, Goligorsky MS: Technology insight: Renal proteomics - at the crossroads between promise and problems. Nat. Clin. Pract. Nephrol. 2, 445-458 (2006).
44. Hoorn EJ, Hoffert JD, Knepper MA: The application of DIGE-based proteomics to renal physiology. Nephron. Physiol. 104, 61-72 (2006).
45. Gonzalez-Buitrago JM, Ferreira L, Lorenzo I: Urinary proteomics. Clin. Chim. Acta 375, 49-56 (2007).
46. Voswinckel P: From uroscopy to urinalysis. Clin. Chim. Acta 297, 5-16 (2000).
47. Bright R: Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hosp. Rep. 1, 338-379 (1836).
48. Bence Jones H: On a new substance occurring In the urine of a patient with mollitles ossium. Philos. Trans. R. Soc. London 138, 55-62 (1848).
49. Simerville JA, Maxted WC, Pahira JJ: Urinalysis: a comprehensive review. Am. Fam. Physician 74, 1153-1162 (2005).
50. Johnson CA, Levey AS, Coresh J et al.: Clinical practice guidelines fbr chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am. Fam. Physician 70, 1091-1097 (2004).
51. Viberti GC, Hill RD, Jarrett RJ et al: Microalbuminuria as a predictor of clinical nephropathy In insulin-dependent diabetes mellitus. Lancet 1430-1432 (1982).
52. Arnlov J, Evans JC, Meigs JB et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112, 969-975 (2005).
53. Sarandis PA, Khosla N, Bakris GL: Antihypertensive therapy in the presence of proteinuria. Am. J. Kidney Dis. 49, 12-26 (2007).
54. Guder WG, Ivandic M. Hoftmann W: Physiopathology of proteinuria and laboratory diagnostic strategy based on single protein analysis. Clin. Chem. Lab. Med. 36, 935-939 (1998).
55. Tencer J, Bakoush O, Tormit O: Diagnostic and prognostic significance of proteinuria selectivity index in glomerular diseases. Clin. Chim. Acta 297, 73-83 (2000).
56. Maachl M, Fellahi S, Regeniter A et al.: Patterns of proteinuria: urinary sodium dodecyl sulfate electrophoresis versus immunonephelometric protein marker measurement followed by interpretation with the knowledge-based system MDI-LabLink. Clin. Chem. 50,1834-1837 (2004).
57. Kuzniar J, Marchewka Z, Krasnowski R et al.: Enzymuria and low-molecular-weight protein excretion as the differentiating marker of complications in the early post kidney transplantation period. Int. Urol. Nephrol. (2006) (Epub ahead of print).
58. Oetting WS, Rogers TB, Krick TP, Matas AJ, Ibrahim HN: Urinary β2-microglobulin is associated with acute renal allograft rejection. Am. J. Kidney Dis. 47, 898-904 (2006).
59. Unay B, Akin R, Sarici SU et al.: Evaluation of renal tubular function in children taking anti-epileptic treatment. Nephrology 11, 485-488 (2006).
60. Kobayashi E, Suwazono Y, Uetani M et al.: Estimation of the benchmark dose as the threshold levels of urinary cadmium, based on excretion of total protein, β2-microglobulin, and N-acetyl-β-D-glucosaminidase in cadmium nonpolluted regions in Japan. Environ. Res 101, 401-406 (2006).
61. Voskaridou E, Terpos E, Michail S et al.: Early markers of renal dysfunction in patients with sickle cell/β-thalassemia. Kidney Int. 69, 2037-2042 (2006).
62. Herget-Rosenthal S, Poppen D, Husing J et al.: Prognostic value of tubular proteinuria and enymuria in nonoliguric acute tubular necrosis. Clin. Chem. 50, 552-558 (2004).
63. Herget-Rsenthal S, Feldkamp T, Volbracht L, Kribben A: Measurement of urinary cystatin C by particle-enhanced nephelornetric Immunoassay: precision, interferences, stability and reference range. Ann. Clin. Biochem. 41, 111-118 (2004).
64. Nakano T, Nagata A, Takahashi H: Ratio of urinary free immunoglobulin light chain κ to χ in the diagnosis of Bence Jones proteinuria. Clin. Chem. Lab. Med. 42, 429-434 (2004).
65. Cole LA, Khanlian SA, Sutton JM, Davies S, Stephens ND: Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection. Clin. Biochem. 36, 647-655 (2003).
66. Khattab AF, Mustafa FA, Taylor PJ: The use of LH detection kits to time intrauterine insemination with donor sperm. Hum. Reprod. 20, 2542-2545 (2005).
67. van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer suveillance: a systematic review. Eur. Urol. 47, 736-748 (2005).
68. Pagard E Francucci CM, Moro L: Markers of bone turnover: biochemical and clinical perspectives. J. Endocrinol. Invest. 28(Suppl. 10), 8-13 (2005).
69. Ivaska KK, Kakonnen SM, Gerdhem P et al.: Urinary osteocalcin as a marker of bone metabolism. Clin. Chem. 51, 618-628 (2005).
70. Buyken AE, Kellerhoff Y, Hahn S, Kroke A, Remer T. Urinary C-peptide excretion in free-living healthy children is related to dietary carbohydrate intake but not to the dietary glycemic index. J. Nutr. 136, 1828-1833(2006).
71. Jang T, Uzbielo A, Sineff S et al.: Point-of-care urine trypsinogen testing for the diagnosis of pancreatitis. Acad. Emerg. Med. 14,29-34 (2007).
72. David WS: Myoglobinuria. Neurol. Clin. 18, 215-243 (2000).
73. Desai S, Bates H, Michalski FJ: Detection of antibody to HIV- I in urine. Lancet 337, 183-184 (1991).
74. Muhsen K, Athamna A, Athamna M, Spungin-Bialik A, Cohen D: Evaluation of a urine-based enzyme-linked immunosorbent assay test for the detection of Helicobacter pylori infection among 3- to 5-year-old Israeli Arab healthy children. Pediatr. Gastroenterol. Nutr. 43, 398-401 (2006).
75. Diederen BM, Peeters MF: Evaluation of two new immunochromatographic assays (Rapid U Legionella antigen test and SD Bioline Legionella antigen test) for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin. Microbiol. 44, 2991-2993 (2006).
76. Cruz I, Chicharro C, Nieto J et al: Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J. Clin. Microbiol. 44, 2343-2347(2006).
77. Stothard JR, Kabatereine NB, Tukahebw EM et al.: Use of circulating cathodic antigen (CCA) dipsticks for detection of intestinal and urinary schistosomiasis. Acta Trop. 97, 219-228 (2006).
78. Matz M, Beyer J, Wunsch D et al: Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 69, 1683-1690 (2006).
79. Hauser IA, Spiegler S, Kiss E et al: Prediction of acute renal allograft rejection by urinary monokine induced by IFN-γ (MIG). J. Am Soc. Nephrol. 16, 1849-1858 (2005).
80. Pugia MJ, Lott JA: Pathophysiology and diagnostic value of urinary trypsin inhibitors. Clin. Chem. Lab. Med. 43, 1-16 (2005).
81. Pugia MJ, Jortani SA, Basu M et ai.: Immunological evaluation of urinary trypsin Inhibitors in blood and urine: role of N- and O-linked glycoproteins. Glyconjug. J. 24, 5-15 (2007).
82. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV: Kidney injury molecule-1: a tissue and urinary biomarker far nephrotoxicant-induced renal injury. Am. J. Renal Physiol. 286, F5524563 (2004),
83. Kamijo-Ikemori A, Sugaya T, Kimura K: Urinary fatty acid binding protein in renal disease. Clin. Chim. Acta 374, 1-7 (2006).
84. Chen L, Jin T, Huang B et al.: Critical exposure level of cadmium for elevated urinary metallothionein - an occupation population study in China. Toxicol. Appl. Pharmacol. 215, 93-99 (2006).
85. Lind SE, Goldshteyn S, Barry CP et al.: Assessment of coagulation system activation using spot urine measurements. Blood Coagul. Fibrinolysis 10, 285-289 (1999).
86. Morris TA, Marsh JJ, Burrows CM et al: Urine and plasma levels of fibrinopeptide B in patients with deep vein thrombosis and pulmonary embolism. Thromb. Res. 110, 159-165 (2003).
87. Yoshikawa R, Wada J, Seiki K et aL Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Res. Clin. Practice (2006) (In Press).
88. Papanikolaou G, Tzilianos M, Christakis JI et al.: Hepcidin in iron overload disorders. Blood 105, 4103-4105 (2005).
89. Kearney SL, Nemeth E, Neufeld EJ et al.: Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer 48, 57-63 (2007).
90. Magid E, Guldager H, Hesse D, Christiansen MS: Monitoring urinary orosomucoid in acute inflammation: observations on urinary excretion of orosomucoid, albumin, α1 -microglobulin, and IgG. Clin. Chem. 51, 2052-2058 (2005).
91. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA: Four tumour makers for urinary bladder cancer - tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res. 25, 635-641 (2005).
92. di Carlo A, Terracciano, D, Mariano A, Macchia V: Urinary gelatinase activities (matrix rnetauoproteinases 2 and 9) in human bladder tumors. Oncol. Rep. 15, 1321-1326 (2006).
93. Wagener G, Jan M, Kim M et al: Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105, 485-491 (2006).
94. Parikh CR, Jani A, Mishra J et al.: Urine NGAL and IL-18 are predictive biomarkers for delayedgraft function following kidney transplantation. Am. J. Transplant. 6, 1639-1645 (2006).
95. Hutchinson LM, Chang EL, Becker CM et al.: Use of thymosin β15 as a urinary biomarker in human prostate cancer. Prostate 64, 116-127 (2005).
96. Helantera I, Teppo AM, Koskinen P et al: Increased urinary excretion of transforming growth factor-β(1) in renal transplant recipients with cytomegalovirus infection. Transpal. Immunol. 15, 217-221 (2006).
97. Li Y, Tucci M, Narain S et al.: Urinary blomarkers In 1upus nephritis. Autoimmun. Rev. 5, 383-388 (2006).
98. Moore CK, Goldman HB: The bladder epithelium and overactive bladder: what we know. Curr. Urol. Rep. 7, 447-449 (2006).
99. Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ: Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology 68,702-706 (2006).
100. Zager RA, Johnson AC, Hanson SY, Lund S: Acute nephrotoxic and obstructive injury primes the kidney to endotoxin-driven cytokine/ chemokine production. Kidney Int. 69-1181-1188 (2006).
101. Ciszek M, Paczek L, Bartiomiejczyk I, Mucha K: Urine cytokines profile in renal transplant patients with asymptomatic bacteriuria. Transplantation 81, 1653-1657 (2006).
102. Schaub S, Wilkins JA, Antonovici M et al: Proteomic-based identification of cleaved urinary β2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J Transplant. 5, 729-738 (2005).
103. Zhou H, Pisitkun T, Aponte A et al.: Exosomal fetuin-A identified by proteomics: a novel urinary biomarker for detecting acute kidney injury. Kidney Int. 70, 1847-1857 (2006).
104. Liu BC, Zhang L, Lu LL et al: Application of antibody array technology in the analysis of urinary cytokine profiles in patients with chronic kidney disease. Am. J. Nephrol. 26, 483-490 (2006).
105. Norden AGW, Sharratt P, Cutillas PR et al: Quantitative amino acid and proteomic analysis: very low excretion of polypeptides > 750 Da in normal urine. Kidney Int. 66, 1994-2003(2004).
106. Hortin GL, Mellinger B: Cross-reactivity of amino acids and other compounds in the biuret reaction: interference with urinary peptide measurements. Clin. Chem. 51, 1411-1419 (2005).
107. Strong KJ, Osicka TM, Comper WD: Urinary-peptide excretion by patients with and volunteers without diabetes. J. Lab, Clin. Med. 145, 239-246 (2005).
108. Hortin GL: The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 52, 1223-1237 (2006).
109. Lou ME Hamilton PB: Separation and quantitation of peptides and an-Ano acids in normal human urine. Meth. Biochem. Anal. 25, 203-271 (1979).
110. Osicka TM, Comper WD: Characterization of immunochemically nonreactive urinary albumin. Clin. Chem. 50, 2286-2291 (2004).
111. Owen WE, Roberts WL: Performance characteristics of an HPLC assay for urinary albumin. Am. J. Clin. Pathol. 124, 219-225 (2005).
112. Polkinghorne KR, Su Q, Chadban SJ et al.: Population prevalence of alburninuria in the Australian diabetes, obesity, and lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am. J. Kidney Dis. 47, 604-613 (2006).
113. Sviridov D, Mellinger B, Drake SK, Hoehn GT Hortin GL: Co-elution of other proteins with albumin during size-exclusion hplc: implications for urine albumin analysis. Clin. Chem. 252, 389-397 (2006).
114. Peters T How should we measure albumin in urine? Clin. Chem. 52, 555-556 (2006).
115. Candiano G, Musante L, Bruschi M et al.: Repetitive fragmentation products of albumin and α1 -antitrypsin in glomerular diseases associated with nephritic syndrome. J. Am. Soc. Nephrol. 17, 3139-3148 (2006).
116. Brenner BM, Hostetter TH, Humes HD: Molecular basis of proteinuria of glomerular origin. N. Engl. J Med. 298, 826-833 (1978).
117. Norden AGW, Lapsley M, Lee PJ et al.: Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int. 60,1885-1892 (2001).
118. Deen WM: What determines glomerular capillary permeabjlity? J. Clin. Invest. 114, 1412-1414,(2004).
119. Vanholder R, De Smet R, Glorieux G et al.: Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 63, 1934-1943 (2003).
120. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev. Drug Discov. 2, 214-221 (2003).
121. Zobel K, Koehler MF, Beresini MH, Caris LD, Combs D: Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. Bioorg. Med. Chem. Lett. 12, 2883-2886 (2002).
122. Christensen EI, Gburek J: Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr. Nephrol. 19, 714-721 (2004).
123. Gekle M: Renal tubule albumin transport. Annu. Rev. Physiol. 67, 573-594 (2005).
124. Negri AL: Proximal tubule endocytic apparatus as the specific renal uptake mechanism for vitamin D-binding protein/25-(OHD3 complex. Nephrology 11, 510-515 (2006).
125. Bond JS, Matters GL, Banerjee S, Dusheck RE: Meprin metalloprotease expression and regulation in kidney, intestine, urinary tract infections and cancer. FMS Let. 579, 3317-3322 (2005).
126. Trof RJ, Di Maggio F, Leemreis J, Groeneveld AB: Biomarkers, of acute renal injury and renal failure. Shock 26, 245-253 (2006).
127. El-Achkar TM, Dagher PC: Renal toll-like receptors: recent advances and implications for disease. Nat. Clin. Prac. Neophrol. 2, 568-581 (2006).
128. Mak RH, Kuo HJ: Pathogenesis of urinary tract infection: an update. Curr. Opin. Pediatr: 18,148-152 (2006).
129. Serafini-Cessi F, Malagolini N, Cavallone D: Tamm-Hoisfall glycoprotein: biology and clinical relevance. Am. J Kidney Dis. 42, 658-676 (2003).
130. Melegos DN, Diamandis EP, Oda H, Urade Y, Hayaishi O: Immunofluorometric assay of prostaglandin D synthase in human tissue extracts and fluids. Clin. Chem. 42, 1984-1991 (1996).
131. Oda H, Shiina Y, Seiki K et al.: Development and evaluation of a practical ELISA for human urinary lipocalin-type prostaglandin D synthase. Clin. Chem. 48, 1445-1453 (2002).
132. Mayo Medical Laboratories: 2006 Test Catalog. MML, Rochester, MN, USA (2006).
133. Bradwell AR: Serum Light Chain Analysis (2nd Edition). The Binding Site, Ltd, Birmingham, UK (2004).
134. Narita T, Sasaki H, Hosoba M et al.: Parallel increase in urinary excretion rates of immunoglobulin G, ceruloplasmin, transferrin, and orosomucoid in normoalburninuric Type 2 diabetic patients. Diabetes Care 27, 1176-1181 (2004).
135. Penders J, Delanghe JR: α1-microglobulin: clinical laboratory aspects and applications. Clin. Chim. Acta 346, 107-118 (2004).
136. Lauridsen AL, Aarup M, Christensen AL et al.: Sensitive automated ELISA for measurement of vitamin D-binding protein (Gc) in human urine. Clin. Chem. 51, 1016-1018 (2005).
137. Tencer J Thysell H, Andersson K, Grubb A: Long-term stability of albumin, protein HC, immunoglobulin G, κ- and λ-chain-immunoreactivity, orosomucoid, and α1-antitrypsin in urine stored at -20 degrees C. Scand. J Urol. Nephrol. 31, 67-71 (1997).
138. Maslamani S, Glenton PA, Khan SR: Changes in urine macromolecular composition during processing. J Urol. 164, 230-236 (2000).
139. Senturk UK, Kuru O, Kocer G, Gunduz.F: Biphasic pattern of exercise-induced proteinuria in sedentary and trained men. Nephron Physiol. 105, 22-32 (2007).
140. Groskopf J, Aubin SM, Deras IL et al.: APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin. Chem. 52, 1089-1095 (2006).
141. Domachevsky L, Grupper M, Shochat T, Adir Y. Proteinuria on dipstick urine analysis after sexual intercourse. BJU Int. 97, 146-148 (2006).
142. Atmani F, Khan SR: Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol. Int 68, 54-59 (2002).
143. Finkel E: Cloudy or clear? Best forecasts for urine cultures. CAP Today 20 (11), 86-90 (2006).
144. Lifshitz E, Kramer L: Outpatient urine culture: does collection technique matter? Arch. Intern. Med. 160, 2537-2540 (2000).
145. Bakker AJ: Immunoturbidimetry of urinary albumin: prevention of adsorption of albumin; influence of other urinary constituents. Clin. Chem. 34, 82-86 (1988).
146. Brinkman JW, de Zeeuw D, Duker JJ et al.: Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin. Chem. 51, 2181-2183 (20.05).
147. Cantin GT, Yates JR 3rd: Strategies for shotgun identification of post-translational modifications by mass spectrometry. J Chromatogr A 1053, 7-14 (2004).
148. Bogdanov B, Smith RD: Proteomics by FTICR mass spectrometry: top down and bottom up. Mass Spectrom. Rev. 24, 168-200 (2005).
149. Hortin GL, Jortani SA, Ritchie JC et al: Proteomics: a new diagnostic frontier. Clin. Chem. 52, 1218-1222(2006).
150. Domon B, Aebersold R: Mass spectrometry and protein analysis. Science 312, 212-217 (2006).
151. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP: Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv. Cancer Res. 96, 23-50 (2007).
152. Julka S, Regnier F: Quantification in proteomics through stable isotope coding: a review. J Proteome Res. 3, 350-363 (2004).
153. Wu WW, Wang G, Baek SJ, Shen RF: Comparative study of three proteomic quantitative methods, DIGE, cICAT, and ITRAQ, using 2D gel- or LC-MALDI TOF/TOF. J. Proteome Res. 5, 651-658 (2006).
154. Hortin GL: Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 51, 3-5 (2005).
155. Anderson L, Hunter CL: Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588 (2006).
156. Fierens C, Stockl D, Baetens D, Leenheer AP, Thienpont LM: Standardization of C-peptide measurements in urine by method comparison with Isotope-dilution mass spectrometry. Clin. Chem. 49, 992-994 (2003).
157. Babic N, Larson TS, Grebe SK, Turner ST, Kumar R, Singh RJ: Application of liquid chromatography-mass spectrometry technology for early detection of microalbuminuria in patients with kidney disease. Clin. Chem. 52, 2155-2157 (2006).
158. Luo Y, Chen M, Wen Q et al.: Rapid and simultaneous quantification of 4 urinary proteins by piezoelectric quartz crystal microbalance immunosensor array. Clin. Chem. 52, 2273-2280(2006).
159. Kricka LJ, Master SR, Joos TO, Fortina P: Current perspectives in protein array technology. Ann. Clin. Biochem. 43, 457-467 (2006).
160. Xiao Z, Adam BL, Cazares LH et al.: Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res. 61, 6029-6033 (2001).
161. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs, KA, Nelson RW: Investigating diversity in human plasma proteins. Proc. Natl. Acad. Sci. 102, 10852-10857 (2005).
162. Petricoin EF, Belluco C, Araujo RP, Liotta LA: The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev Cancer 6, 961-967 (2006).
163. Lopez MF, Mikulskis A, Kuzdzal S et al: High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51, 1946-1954 (2005).
164. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. Nature 422, 233-237 (2003).
165. Palagi PM, Hernandez P, Walther D, Appel RD: Proteome informatics I: bioinformatics tools for processing experimental data. Proteomics 6, 5435-5444 (2006).
166. States DJ, Omenn GS, Blackwell TW et al: Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat. Biotechnol. 24, 333-338 (2006).
167. Ransohoff DF: Bias as a threat to the validity of cancer molecular-marker research. Nat. Rev. Cancer 5, 142-149 (2005).
168. Vitzthum F, Behrens F, Anderson NL, Shaw JH: Proteomics for basic research to diagnostic application. A review of requirements and needs. J. Proteome Res 4, 1086-1097 (2005).
169. Master SR: Diagnostic,proteomics: back to basics? Clin. Chem. 51, 1333-1334 (2005).